Precision BioSciences (NASDAQ:DTIL) Insider J. Jefferson Smith Sells 10,200 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,200 shares of the firm’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total transaction of $41,106.00. Following the completion of the transaction, the insider directly owned 110,184 shares of the company’s stock, valued at approximately $444,041.52. The trade was a 8.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Precision BioSciences Trading Up 6.0%

Precision BioSciences stock opened at $4.25 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 3.45 and a current ratio of 3.45. Precision BioSciences, Inc. has a fifty-two week low of $3.75 and a fifty-two week high of $8.82. The stock has a market cap of $56.36 million, a P/E ratio of -0.51 and a beta of 1.20. The firm’s fifty day moving average price is $4.59 and its 200-day moving average price is $5.12.

Precision BioSciences (NASDAQ:DTIL) last posted its earnings results on Monday, November 3rd. The company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $5.40 million. Precision BioSciences had a negative return on equity of 233.77% and a negative net margin of 11,977.36%.During the same quarter in the previous year, the firm earned ($2.25) earnings per share. Equities research analysts forecast that Precision BioSciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $60.00.

Institutional Trading of Precision BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Precision BioSciences during the third quarter worth approximately $72,000. Virtu Financial LLC purchased a new stake in shares of Precision BioSciences in the 3rd quarter valued at $84,000. GSA Capital Partners LLP bought a new position in shares of Precision BioSciences during the 3rd quarter valued at $98,000. Velan Capital Investment Management LP bought a new position in shares of Precision BioSciences during the 3rd quarter valued at $110,000. Finally, Citadel Advisors LLC purchased a new position in Precision BioSciences in the 3rd quarter worth $122,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.